NCT06394232: Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 54 planned
- Started
- 4 Jun 2024
- Primary completion
- Apr 2025
- Arms
- Dose Level 1-Cohort 1, Dose Level 2-Cohort 2, Dose Level 3-Cohort 3
- Results
- None posted
- 1 May 2024: Trial registered
- 4 Jun 2024: Trial started